DIAGNOSTIC AND PROGNOSTIC VALUE OF RENAL TUBULAR INJURY BIOMARKERS NGAL, KIM-1, L-FABP IN CHRONIC KIDNEY DISEASE PATIENTS
https://doi.org/10.24884/1561-6274-2017-21-2-24-32
Abstract
The review summarized data on the diagnostic and prognostic value of biomarkers of kidney injury NGAL (neutrophil gelatinaseassociated lipocalin), KIM-1 (kidney injury molecule-1) and L-FABP (liver type fatty acid-binding protein) in patients with CKD. The most studied of these is NGAL, increase of its level in urine reflects the severity of CKD. Elevated levels of urinary NGAL evaluated also as a prognostic criterion which allows identifying patients with high risk of unfavorable course of disease. Elevated levels of urinary KIM-1 inpatients with CHF can detect individuals with tubulointerstitial kidney injury, having an adverse prognostic value, and to assess their risk of death or rehospitalization about CHF. Data obtained in large populations of patients with diabetes type 1 and 2 with CKD show that high levels of urinary L-FABP is associated with an increased risk of diabetic nephropathy progression. High levels of this biomarker in urine of patients with diabetes type 2 and stage1-2 CKD is also unfavorable prognostic marker of increased risk of coronary heart disease and other cardiovascular complications. In general, diagnostic and prognostic value of urine KIM-1 and L-FABP in CKD patients with varying severity poorly understood and needs further clinical studies.
About the Authors
O. B. Kuzmin
Orenburg State Medical University
Russian Federation
Prof. Oleg B Kuzmin MD, PhD, DMedSci
Russian Federation
Prof. Oleg B Kuzmin MD, PhD, DMedSci
Department of Pharmacology.
460000 Russia, Orenburg, Park st., 7.
V. V. Zhezha
Orenburg State Medical University
Russian Federation
Russian Federation
Associate prof. Vladislav V Zhezha, Department of Pharmacology.
460000 Russia, Orenburg, Park st., 7.
V. V. Belaynin
Orenburg State Medical University
Russian Federation
Vitaly V Belyanin, Department of Pharmacology.
Russian Federation
Vitaly V Belyanin, Department of Pharmacology.
460000 Russia, Orenburg, Park st., 7.
N. V. Buchneva
Orenburg State Medical University
Russian Federation
Natalya V. Buchneva Vladislav V Zhezha, Department of Pharmacology.
Russian Federation
Natalya V. Buchneva Vladislav V Zhezha, Department of Pharmacology.
460000 Russia, Orenburg, Park st., 7.
L. N. Landar
Orenburg State Medical University
Russian Federation
Larisa N Landar, Department of Pharmacology.
Russian Federation
Larisa N Landar, Department of Pharmacology.
460000 Russia, Orenburg, Park st., 7.
S. V. Serdyuk
Orenburg State Medical University
Russian Federation
Russian Federation
Svetlana V. Serdyuk, Department of Pharmacology.
460000 Russia, Orenburg, Park st., 7.
References
1. Coca SG, Valavarthy R, Concabo J et al. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int 2008; 73 (10): 1008-1016 doi: 10.1038/ sj.ki.5002729
2. McCullough PA, Shaw AD, Haase M et al. Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative consensus conference. Contrib Nephrol 2013; 182: 13-29 doi: 10.1059/000349963
3. Смирнов АВ, Добронравов ВА, Румянцев АШ и др. Национальные рекомендации. Острое повреждение почек: основные принципы диагностики, профилактики и терапии. Часть 1. Нефрология 2016; 20 (1): 79-104 [Smirnov AV, Dobronravov VA, Rumyantsev ASh i dr. Natsionalnyye recomendatsii. Ostroye povrezhdeniye pochek: Osnovnyye printsipy diagnostiki, profilactiki i terapii. Nefrologiya 2016; 20 (1): 79-104]
4. Paragas N, Qiu A, Zhang Q et al. The NGAL reporter mouse detects the response of the kidney injury in real time. Nature Medicine 2011; 17 (2): 216-222 doi: 10.1038/nm.2290
5. Kuwabara T, Mori K, Mukoyama M et al. Urinary neutrophil gelatinase-associated lipocalin levels reflects damage to glomeruli, proximal tubules and distal nephrons. Kidney Int 2009; 75 (3): 285-294 doi: 10.1038/ki.2008.499
6. Zang XJ, An SX, Feng Z et al. In vivo mechanism study of NGAL in rat renal ischemia-reperfusion injury. Genet Mol Res 2014; 13 (4): 8740-8748 doi: 10.4238/2014.October.27.15
7. Viau A, Karoui KE, Laouari D. Lipocalin 2 is essential for chronic kidney disease in mice and human. J Clin Invest 2010; 120 (11): 4065-4076 doi: 10.1172/JC142004
8. Singer E, Marko L, Paragas N et al. Neutrophil gelatinaseassociated lipocalin: pathophysiology and clinical implications. Acta Physiol (Oxf.) 2013; 207 (4): 663-672 doi: 10.1111/alpha. 12054
9. Khan Z, Pandey M. Role of kidney biomarkers in chronic kidney disease: an update. Saudi J Biol Sci 2014; 21 (4): 294-299 doi: 10.1016/j.sjbs.2014.07.003
10. Xiang GD, Zhang H, Bai Y et al. Clinical applications of neutrophil gelatinase-associated lipocalin in the revised chronic kidney disease classification. Int J Clin Exp Pathol 2014; 7 (10): 7172-7181
11. Bolignano D, Laquaniti A, Coppolino G. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of kidney disease. CJASN 2009; 4 (2): 337-344 doi: 10.2215/CJN.03530708
12. Smith ER, Lee D, Cai MM et al. Urinary neutrophil gelatinaseassociated lipocalin may aid prediction of renal decline in patients with non proteinuric stages 3 and 4 chronic kidney disease (CKD). Nephrol Dial Transplant 2013; 28 (6): 1569-1579 doi: 10.1093/ndt/gfs.586
13. Liu KD, Yang W, Go AS, Anderson AH, Feldman HI, Fisher MJ et al. Chronic Renal Insufficiency Cohort (CRIS) study investigators. Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease. Kidney Int 2013; 83 (5): 909-914. doi: 10.1053/j.ajkd.2014.025
14. Lin HY, Hwang DY, Lee SC et al. Urinary neutrophil gelatinaseassociated lipocalin and clinical outcomes in chronic kidney disease patients. Clin Chem Lab Med 2015; 53 (1): 73-83 doi: 10.1515/ccim-2014-0647
15. Hasegawa M, Ishii J, Katagawa F et al. Urinary neutrophil gelatinase-associated lipocalin as a predictor of cardiovascular events in patients with chronic kidney disease. Heart Vessels 2015; 30 (1): 81-88 doi: 10.1007/s00380-013-0454-7
16. Liu KD, Yang W, Go AS et al. Urine neutrophil gelatinaseassociated lipocalin and risk cardiovascular disease and death in CKD: results from the Chronic Renal Insufficiency Cohort (CRIS) study. Am J Kidney Dis 2015; 65 (2): 267-274 doi: 10.1053/j. ajkd.2014.07.025
17. Patel ML, Sachan R, Verma A et al. Neutrophil gelatinaseassociated lipocalin as a biomarker of disease progression in patients with chronic kidney disease. Indian J Nephrol 2016; 26 (2): 125-130 doi: 10.4103/0971-4065.157799
18. Ichimura T, Asseldonk EJ, Humphreys BD et al. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocyte phenotype on epithelial cells. J Clin Invest 2008; 118 (5): 1657-1668 doi: 10.1172/JCI34487
19. Bonventre JV. Kidney injury molecule-1: a translational journey. Trans Am Clin Climatol Assoc 2014; 125: 293-299
20. Lim AI, Tanq SC, Lai KN, Leung JC. Kidney injury molecule1: more than just an injury marker of the epithelial cells. J Cell Physiol 2013; 228 (5): 917-924. doi: 10.1002/jcp.24267
21. Zhang Z, Cai CX. Kidney injury molecule-1 (KIM-1) mediates renal epithelial cell repair via ERK MAPK signaling pathway. Mol Cell Biophem 2016; 416 (1-2): 109-116 doi: 10.1007/s11010016-2700-7
22. Humphreys BD, Xu F, Sabbisetti V et al. Chronic kidney injury molecule-1 expression causes murine kidney fibrosis. J Clin Invest 2013; 123 (9): 4023-4035 doi: 10.1172/JCI45361
23. Van Timmeren MM, van den Heuvel MC, Bailly V et al. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 2007; 212 (2): 209-217 doi: 10.102/path.2175
24. Xu PC, Wei L, Shang WY et al. Urinary kidney injury molecule1 is reflect to pathologic involvement in IgA nephropathy with normotension, normal renal function and mild proteinuria. BMC Nephrol 2014; 15: 107 doi: 10.1186/1471-2369-15-107
25. Waanders F, Vaidya VS, van Goor H et al. Effect of reninangiotensinaldosterone system inhibition, dietary sodium restriction and/or diuretics on urinary kidney injury molecule-1 excretion on nondiabetic proteinuric kidney disease. Am J Kidney Dis 2009; 53 (1): 16-25 doi: 10.1053/j.ajkd.2008.07.021
26. Peters HP, Waanders F, Meijer E et al. High urinary excretion of kidney injury molecule-1 is an independent predictor for end-stage renal disease in patients with IgA nephropathy. Nephrol Dial Transplant 2011; 26 (11): 3581-3588 doi: 10.1093/ndt/gfr135
27. Jungbauer CG, Birner C, Jung B et al. Kidney injury molecule-1 and N-acetyl-β-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur J Heart Fail 2011; 13 (10): 1104-1110 doi: 10.1093/eurjhf/hfr102
28. Damman K, Masson S, Hillege HL et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J 2011; 32 (21): 2705-2712 doi: 10.1093/eurheartj/ehr190
29. Damman K, Masson S, Hillege HL et al. Tubular damage and worsening renal function in chronic heart failure. JACC Heart Fail 2013; 1 (5): 417-425 doi: 10.1016/j.jchf.2013.05.007
30. Кузьмин ОБ, Белянин ВВ, Жежа ВВ. Легкая дисфункция почек у больных сердечной недостаточностью: доклинические признаки и их прогностическое значение. Журн Сердечная недостаточность 2014; 15 (2): 126-131 [Kuzmin OB, Belyanin VV, Zhezha VV. Legkaya disfunctsiya pochek u bolnyih serdechnouy nedostatochnotyu: doklinicheskie priznaki i ih prognosticheskoe znachenie. Zhurnal Serdechnaya nedostatochnost 2014; 15 (2): 126-131]
31. Yamamoto T, Noiri E, Ono Y et al. Renal L- type fatty acidbinding protein in acute ischemic injury. J Am Soc Nephrol 2007; 18 (11): 2894-2902 doi: 10.1681/ASN.2007010097
32. Yokoyama T, Kamijo-Ikemori A, Sugaya T et al. Urinary excretion of liver type fatty acid-binding protein accurately reflects the degree of tubulointerstitial damage. Am J Pathol 2009; 174 (6): 2096-2106 doi: 10.2353/ajpath.2009.080780
33. Osaki K, Suzuki Y, Sugaya T et al. Amelioration of angiotensin II-induced salt-sensitive hypertension by liver type fatty acid-binding protein in proximal tubules. Hypertension 2013; 62 (4): 712-718 doi: 10.1161/HYPERTENSIONAHA.113.01203
34. Ichikawa D, Kamijo-Ikemori A, Sugaya T et al. Renoprotective effect of renal liver type fatty acid-binding protein and angiotensin II type 1α receptor loss in renal injury caused by RAS activation. Am J Physiol Renal Physiol 2014; 306 (6): F655-F663 doi: 10.1152/ajprenal.00460.2013
35. Nakamura T, Sugaya T, Kawagoe Y et al. Effect of pitavastatin on urinary liver type fatty acid-binding protein in patients with nondiabetic mild chronic kidney disease. Am J Nephrol 2006; 26 (1): 82-86 doi: 10.1159/000091956
36. Nakamura T, Sugaya T, Kawagoe Y et al. Effect of erythropoietin on urinary liver type fatty acid-binding protein in patients with chronic renal failure and anemia. Am J Nephrol 2006; 26 (3): 276-280 doi: 10.1159/000093960
37. Kamijo A, Sugava T, Nikawa A et al. Clinical evaluation of urinary excretion on liver type fatty acid-binding protein as a marker to the monitoring of chronic kidney disease. A multicenter trial. J Lab Clin Med 2005; 145 (3): 125-133 doi: 10.1016/j. lab.2004.12.003
38. Mou S, Wang Q, Li J et al. Urinary excretion of liver type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis. Clin Chim Acta 2012; 413 (1-2): 187-191 doi: 10.1016/j.cca.2011.09.018
39. Matsui K, Kamijo-Ikemori A, Imai N et al. Clinical significance of urinary liver-type acid binding protein as a predictor of ESRD and CVD in patients with CKD. Clin Exp Nephrol 2016; 20 (2): 195-203 doi: 10.1007/s10157-015-1144-9
40. Panduru N, Forsblom C, Saraheimo M et al. Urinary liver type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2013; 36 (7): 20772083 doi: 10.2337/dc12-1868
41. Araki S, Haneda M, Koya D et al. Predictive effect of urinary liver type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care 2013; 36 (5): 12481253 doi: 10.2337/dc12-1491
Review
For citations:
Kuzmin O.B., Zhezha V.V., Belaynin V.V., Buchneva N.V., Landar L.N., Serdyuk S.V. DIAGNOSTIC AND PROGNOSTIC VALUE OF RENAL TUBULAR INJURY BIOMARKERS NGAL, KIM-1, L-FABP IN CHRONIC KIDNEY DISEASE PATIENTS. Nephrology (Saint-Petersburg). 2017;21(2):24-32. (In Russ.) https://doi.org/10.24884/1561-6274-2017-21-2-24-32
Views:
1474
Email this article 